Table 1. Baseline characteristics of three patients failing on raltegravir-containing regimens.

Patient	VL	CD4	Co-prescribed drugs	RT mutations	PR mutations	GSS
1	6.7	16	ETR/DRV/r	41L 44D 67N 69D/N 74I 75T 101E 179F 181C 184V 190S 210W 215Y	10F 15V 20R 32I 33F 36I 50V 54A 62V 63P 71V 84V 85V 89V 90M	0
2	6.4	36	ETR/DRV/r/ENF	41L 44D 67N 74V 103N 184V 210W 215Y	10F/V 15V 20R 33F 46I 62V 63P 71T 73S 76V 84V 89V 90M	1
3	5.6	22	TDF/FTC/ETR/DRV/r	41L 44D 67N 70R 181C 184V 190A 210W 215Y	10V 15V 20R 32I 33F 46I 54V 58E 63P 82A 84V 90M	0

Abbreviations: VL: Viral load (Plasma HIV-1 RNA), log₁₀copies/ml; CD4: CD4 (+) cell count (cells/µl); GSS: Genotypic sensitivity score;

TDF: tenofovir diphospho fumarate; ETR: etravirine; DRV/r: darunavir boosted with ritonavir; ENF: enfuvirtide; FTC: emtricitabine.